COMMUNIQUÉS West-GlobeNewswire

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
24/09/2024
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience [...]
Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation
24/09/2024
PARAMUS, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal [...]
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24/09/2024
Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease. An estimated one in 100 people globally suffer from celiac disease, for which no approved [...]
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
24/09/2024
Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurology SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: [...]
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
24/09/2024
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]
Certara’s Simcyp Consortium Celebrates 25th Anniversary
24/09/2024
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisions RADNOR [...]
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
23/09/2024
Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the [...]
DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE
23/09/2024
Châtillon, France, le 23 septembre 2024 (22 :30 CEST) DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE DBV a dépassé son objectif de recrutement, clôturant avec succès au troisième [...]
BioVie Inc. Announces Proposed Public Offering
23/09/2024
CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and [...]
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database
23/09/2024
QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO [...]
Comprehensive Urology Studies ED Injections with Shockwave Therapy for Penile Girth Enhancement
23/09/2024
LOS ANGELES, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Comprehensive Urology has opened another round of observational studies for the STUD Protocol for male enhancement as part of their Prostate Cancer Awareness Month events [...]
SAFE Group - Report d’audience d’examen des plans de redressements au 18 octobre 2024
23/09/2024
Fleurieux-sur-l’Arbresle - France - le 23 septembre 2024 à 20h10 . Safe SA (la « Société ») annonce le renvoi de l’audience d’examen des plans de redressements au 18 octobre 2024. Ce renvoi a été sollicité dans l’ [...]
La quadrithérapie à base de DARZALEX® (daratumumab) reçoit un avis favorable de la part du CMUH pour les patients atteints d’un myélome multiple nouvellement diagnostiqué et éligibles à une greffe
23/09/2024
Cette recommandation est étayée par les résultats de l’étude PERSEUS portant sur la quadrithérapie avec daratumumab en formulation sous-cutanée (SC) en traitement de première ligne Les résultats ont révélé une réduction [...]
Life Sciences Week 2024: Advancing Innovation, Investment, and Collaboration in Alberta’s Life Sciences Sector
23/09/2024
EDMONTON, Alberta, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Life Sciences Week, Alberta’s flagship event for showcasing the life sciences sector, returns from September 23 to 27, 2024, projecting an estimated 3,000 attendees [...]
Nortem BioGroup releases its annual results for the 2023 financial year
23/09/2024
Nortem BioGroup (EPA:MLBIO) (MLBIO.PA), a Euronext-listed company and a leader in the European food biotechnology sector, has released its annual results for the 2023 financial year. Interested investors can download [...]
SPINEWAY: Half-year financial statements 2024
23/09/2024
SPINEWAY Half-year financial statements 2024 Attachment Consolidated financial statements – 06 30 2024
SPINEWAY : Rapport semestriel 2024
23/09/2024
SPINEWAY Comptes semestriels 2024 et rapport d'activité Pièce jointe RFS_S12024
Crossject reports financial results and business highlights for the first six months of 2024
23/09/2024
Available cash €5.95 million, up from €2.3 million on December 31, 2023 Reports stable investments in R&D and consolidation of operating income from BARDA Company on track to successfully file for the Emergency Use [...]
Crossject présente ses résultats financiers et les faits marquants de ses activités pour le premier semestre 2024
23/09/2024
Position de trésorerie : 5,95 millions d'euros, contre 2,3 millions d’euros au 31 décembre 2023 Investissements stables en R&D et consolidation des revenus d'exploitation de BARDA La société est en bonne voie pour [...]

Pages